Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Glucotrojan** is a powdered dietary supplement formulated to support normal glucose metabolism, blood sugar balance, and healthy insulin response[2][5][6]. The supplement contains extracts of white mulberry leaf (Morus alba), mango leaf (Mangifera indica), and stem banana (Musa spp.), primarily standardized for Reducose®, a patented extract rich in iminosugars such as 1-deoxynojirimycin (DNJ)[1][6]. DNJ acts as a potent inhibitor of alpha-glucosidase enzymes in the gut, reducing carbohydrate absorption, slowing the conversion of starches and sugars to glucose, and promoting healthier postprandial blood glucose and insulin profiles[1][6]. Clinical trials and real-world studies have shown that Reducose® (mulberry extract) in Glucotrojan lowers postprandial blood glucose response by up to 40% when consumed with carbohydrate-rich meals, particularly targeting populations with prediabetes, normoglycemia, and non-insulin-dependent diabetes. The product is intended as a meal companion powder or capsule to be added to foods, drinks, or taken directly[2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Glucotrojan.